Cancer, rheumatism, asthma: organ-on-chip models highly relevant for preclinical testing of therapeutic antibodies
Improving people’s lives with innovative technologies. This was the goal that Jena-based Dynamic42 had in mind 18 months ago when they launched a project – funded as part of the Sanofi iDEA-iTECH Award Program – to investigate the pharmacokinetic properties of drugs in a biochip-based organ model. Initial results were presented at this year’s MPS World Summit in Seattle in mid-June and at the annual meeting of the European Organ-on-chip society (EUROoCS) in Milan at the beginning of July.
Dynamic42 GmbH, founded in 2018 by employees of Jena University Hospital, specializes in 3D in-vitro test systems known as “organs-on-chip” (OoC). In these biochip-based microfluidic systems, researchers replicate human physiology in the laboratory – human cells react in vitro almost as they do in vivo.
Recycling, viability and vascular permeability of two frequently used mAbs were analyzed using this liver-on-chip model. “We were able to verify the recycling process of therapeutic antibodies without compromising cell viability or tissue integrity. Our model helps to overcome the species specificity of animal models and thereby can reduce the frequency of failures in clinical trials.” Anne-Katrin Bothe at Dynamic42, summarizes the results.
The project partners aim to continue their joint efforts on innovative organ-on-chip technology for the characterization of the disposition of new therapeutic antibodies.
About Dynamic42 GmbH
D42 was founded in 2018 as a spin-off of the Jena University Hospital. The start-up develops and sells human microphysiological systems (organ-on-chip technology) that enable toxicity screenings and ADMET studies.
Read more News:
Amélie Marie Paillereau joins Dynamic42 as Master Student funded by the Thuringia and European Social Fund Plus
We are excited to welcome Amélie Marie Paillereau to the Dynamic42 science team. Amélie started in April with us for a 12-month-long Master thesis, focusing on perfused breast and pancreatic cancer-on-chip models to study the impact of the tumor microenvironment on immune cell invasion.
ATHANA alliance for antifungal therapy approaches – First strategy workshop
The RUBIN alliance “ATHANA” met for their first strategy workshop one year after the project kicked off in summer last year.
Joanna Nowacka joins Dynamic42 as Lead for Stem Cell Model Development
We are delighted to announce that Joanna Nowacka has joined Dynamic42 as Lead for Stem Cell Model Development.